UofM Chief Health Officer Details How Phase 3 of COVID Vaccine Trials Can Be Best Tested

Dr. Preeti Malani, Chief Health Officer & Professor of Medicine in the Division of Infectious Diseases, University of Michigan, says that vaccinating a large number of people in areas of exposure risk are among the keys in determining effectiveness of a COVID-19 vaccine, whereas areas of less exposure will not see a difference in effectiveness between the vaccine and placebo recipients if a trial is performed in a less COVID-risky population.

Stay up to date with our videos by subscribing to our channel: https://www.youtube.com/user/CivicCenterTV15?sub_confirmation=1.
Visit our website for more information on the Megacast and Coronavirus: https://civiccentertv.com/
Follow us ⬇ ⬇